ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-01

Study Completion Date

2022-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels. In particular, visceral fat is accompanied by more alterations in glucose and lipid metabolism. Quantification of visceral fat with bioimpedance (BIA) is closely related to measurement with computed axial tomography. Different available oral antidiabetics cause weight loss and total body fat (biguanides, DPP-4 inhibitors and SGLT-2 inhibitors), but it has only been shown that SLGT2 inhibitors decrease visceral fat. Therefore, the aim of this study is to determine whether there is a difference in the amount of visceral fat measured with BIA in T2D patients between three oral antidiabetic regimens after twelve weeks of treatment, to compare the effect on visceral fat between metformin, DPP4 inhibitors and SGLT2 inhibitors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver

NCT05202353

Obesity

RECRUITING PHASE1

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

NCT05005741

Diabetes Mellitus, Type 2 Overweight or Obesity

UNKNOWN PHASE4

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

NCT05669599

Obesity Overweight Type 2 Diabetes Mellitus

COMPLETED PHASE2

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

NCT06615700

Overweight or Obesity Type 2 Diabetes

COMPLETED PHASE1

Study of Patients Being Treated With Anti-obesity Medication

NCT06790160

Obesity and Overweight

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Obesity Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

Metformin 1.7-2.5mg per day during twelve weeks

Group Type EXPERIMENTAL

Biguanide, DPP4 inhibitors, SGLT2 inhibitors

Intervention Type DRUG

Oral antidiabetic treatment during twelve weeks

Metformina + IDDP-4

Metformin 1.7-2.5mg per day plus Linagliptin 5mg per day or Sitagliptin 50-100mg per day

Group Type EXPERIMENTAL

Biguanide, DPP4 inhibitors, SGLT2 inhibitors

Intervention Type DRUG

Oral antidiabetic treatment during twelve weeks

Metformina + ISGLT-2

Metformin 1.7-2.5mg per day plus Empaglifozin 10-25mg per day or Dapaglifozin 10mg per day

Group Type EXPERIMENTAL

Biguanide, DPP4 inhibitors, SGLT2 inhibitors

Intervention Type DRUG

Oral antidiabetic treatment during twelve weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biguanide, DPP4 inhibitors, SGLT2 inhibitors

Oral antidiabetic treatment during twelve weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients +18 years
* Patients with visceral fat quantification by BIA at baseline and week twelve
* Patients with body mass index \>25
* Patients can swallow tablets

Exclusion Criteria

* Patients treated with other oral antidiabetic agents or insulin
* Glomerular filtration rate less than 30 mL/min
* Transaminemia greater than 2 times the upper reference value
* Pregnancy
* Malnutrition

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No